All In Biotech

Drug Trial Radar · NCT05304715

Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection

Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection: The BEYOND Double-Blind Randomized Clinical Trial

Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

44

Actual

Start

Apr 13, 2022

Primary completion

Jun 4, 2023

Study completion Jun 4, 2023

Sponsor

Lead sponsor
Hellenic Institute for the Study of SepsisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Previous data have shown that integrated information from single nucleotide polymorphisms (SNPs) of the host DNA, interleukin 8 (IL-8) and the enrichment of the stool microbiome can indicate the patients with infection by Clostridioides difficile (CDI) who are at risk for unfavorable outcome. This integrated information is forming the BEYOND score. The aim of the BEYOND randomized clinical trial (RCT) is to investigate if adjunctive bezlotoxumab treatment to the current standard-of-care may decrease the likelihood of unfavorable outcome for patients who score positive by the BEYOND score.

Conditions

  • Clostridioides Difficile Infection
  • Stool Microbiome
  • Organ Dysfunction Syndrome
  • Clostridioides Difficile Infection Recurrence
  • Mortality

Interventions

  • BezlotoxumabDrug

    Single intravenous infusion of bezlotoxumab

  • Normal saline 0.9% or 5% dextrose waterDrug

    Single intravenous infusion - Placebo arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Superiority of Bezlotoxumab Over Placebo to Reduce the Occurence of an Unfavorable Outcome by Day 40.Time frame: 40 days

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • 2nd Department of Internal Medicine, University General Hospital of Alexandroupolis

    Alexandroupoli, Greece

  • 1st Department of Internal Medicine, THRIASIO General Hospital of Eleusis

    Athens, Greece

  • 2nd Department of Internal Medicine, Thriasio General Hospital

    Athens, Greece

  • 1st University Department of Internal Medicine, LAIKO General Hospital of Athens,

    Athens, Greece

  • 1st University Department of Propaedeutic Surgery, IPPOKRATEION General Hospital

    Athens, Greece

  • 4th Department of Internal Medicine, Attikon University Hospital

    Athens, Greece

  • 1st Department of Internal Medicine, General University Hospital of Ioannina

    Ioannina, Greece

  • Department of Internal Medicine, Larissa University Hospital

    Larissa, Greece

  • Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA

    Pátrai, Greece

  • 2nd Department of Internal Medicine, Tzanneion General Hospital

    Piraeus, Greece

  • 1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki

    Thessaloniki, Greece

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.